October 1998
Volume 39, Issue 11
Free
Articles  |   October 1998
Rabbit Streptococcus pneumoniae keratitis model and topical therapy.
Author Affiliations
  • J P Guzek
    Margaret Marquart Catholic Hospital, Kpando, Ghana, West Africa.
  • D J Cline
    Margaret Marquart Catholic Hospital, Kpando, Ghana, West Africa.
  • P K Row
    Margaret Marquart Catholic Hospital, Kpando, Ghana, West Africa.
  • I F Wessels
    Margaret Marquart Catholic Hospital, Kpando, Ghana, West Africa.
  • S Beeve
    Margaret Marquart Catholic Hospital, Kpando, Ghana, West Africa.
  • S Ispirescu
    Margaret Marquart Catholic Hospital, Kpando, Ghana, West Africa.
  • R M Aprecio
    Margaret Marquart Catholic Hospital, Kpando, Ghana, West Africa.
  • J D Kettering
    Margaret Marquart Catholic Hospital, Kpando, Ghana, West Africa.
  • D L Gano
    Margaret Marquart Catholic Hospital, Kpando, Ghana, West Africa.
  • G M Nelson
    Margaret Marquart Catholic Hospital, Kpando, Ghana, West Africa.
Investigative Ophthalmology & Visual Science October 1998, Vol.39, 2012-2017. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J P Guzek, D J Cline, P K Row, I F Wessels, S Beeve, S Ispirescu, R M Aprecio, J D Kettering, D L Gano, G M Nelson; Rabbit Streptococcus pneumoniae keratitis model and topical therapy.. Invest. Ophthalmol. Vis. Sci. 1998;39(11):2012-2017.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
This content is PDF only. Please click on the PDF icon to access.
Abstract

PURPOSE: To develop a model for experimental Streptococcus pneumoniae keratitis and to evaluate the chemotherapeutic efficacy of 12 common topical antibiotics in vivo. METHODS: Five-hundred (CFUs of log-phase S. pneumoniae were injected into the central corneal stroma of 36 eyes of 18 rabbits. After 0, 4, 8, 16, 24, and 48 hours, the in vivo growth was assayed as the CFU per cornea. Epithelial removal (to promote antibiotic entry and mimic human keratitis) was evaluated. Disc or tube dilution verification of the sensitivity or resistance of three S. pneumoniae strains was performed: a penicillin sensitive ("S"), an intermediate sensitive ("I"), and a resistant ("R") strain. Keratitis was established with S. pneumoniae "S" in 65 eyes, S. pneumoniae "I" in 107 eyes, and S. pneumoniae "R" in 78 eyes. Sixteen hours later, control corneas were harvested and the epithelium removed from treatment corneas. Every half hour saline, penicillin, gentamicin, bacitracin, ciprofloxacin, ofloxacin, erythromycin, vancomycin, ceftriaxone, cefotaxime, or chloramphenicol was applied for 5 hours. One hour later CFUs/cornea were assayed. RESULTS: After 24 hours, S. pneumoniae "S" and "I" had proliferated to 9.18+/-6.65 x 10(6) CFUs and 9.26+/-6.90 x 10(6) CFUs. Epithelial removal at 16 hours was not significant. The in vitro antibiotic sensitivity was as expected. However, in vivo, penicillin, gentamicin, or cefazolin sterilized S. pneumoniae "S." S. pneumoniae "R" responded best to fortified gentamicin with or without vancomycin; all others antibiotics were significantly less effective (P < 0.001). CONCLUSIONS: A small intracorneal S. pneumoniae inoculum in rabbit corneas grew and was maintained for 24 hours (with epithelial removal) to provide a model for testing antibiotic sensitivity in vivo. Topical penicillin is best for treating keratitis from penicillin-sensitive S. pneumoniae, whereas topical gentamicin or a combination of gentamicin and vancomycin was most effective against penicillin-resistant S. pneumoniae.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×